Drilon, Alexander http://orcid.org/0000-0001-6806-9061
Jenkins, Chelsea http://orcid.org/0000-0002-9403-0619
Iyer, Sudarshan http://orcid.org/0000-0001-7837-1854
Schoenfeld, Adam
Keddy, Clare
Davare, Monika A.
Article History
Accepted: 15 June 2020
First Online: 5 August 2020
Competing interests
: A.D. has received honoraria from or participated on the advisory boards of 14ner/Elevation Oncology, Abbvie, ArcherDX, AstraZeneca, Beigene, BergenBio, Blueprint Medicines, Exelixis, Helsinn, Hengrui Therapeutics, Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Monopteros, MORE Health, Pfizer, Remedica, Takeda/Ariad/Millenium, TP Therapeutics, Tyra Biosciences and Verastem; research support paid to his institution from Exelixis, GlaxoSmithKlein, Pfizer, PharmaMar, Taiho and Teva; research support from Foundation Medicine; personal fees from Boehringer Ingelheim, Merck, Merus and Puma; and CME honoraria from Axis, Medscape, OncLive, Paradigm Medical Communications, Peerview Institute, PeerVoice, Physicians Education Resources, Research to Practice, Targeted Oncology and WebMD. The other authors declare no competing interests.